BrightGene Bio-Medical Technology Past Earnings Performance
We're still processing the latest earnings report of this company
Past criteria checks 2/6
BrightGene Bio-Medical Technology has been growing earnings at an average annual rate of 20.9%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been growing at an average rate of 21% per year. BrightGene Bio-Medical Technology's return on equity is 8.2%, and it has net margins of 16.7%.
Key information
20.9%
Earnings growth rate
18.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 21.0% |
| Return on equity | 8.2% |
| Net Margin | 16.7% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How BrightGene Bio-Medical Technology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1,200 | 201 | 0 | 0 |
| 30 Sep 23 | 1,160 | 234 | 178 | 232 |
| 30 Jun 23 | 1,104 | 237 | 166 | 217 |
| 31 Mar 23 | 1,074 | 250 | 186 | 213 |
| 31 Dec 22 | 1,017 | 240 | 183 | 207 |
| 30 Sep 22 | 1,076 | 265 | 193 | 193 |
| 30 Jun 22 | 1,074 | 249 | 187 | 189 |
| 31 Mar 22 | 1,112 | 256 | 170 | 194 |
| 31 Dec 21 | 1,052 | 244 | 156 | 173 |
| 30 Sep 21 | 1,023 | 225 | 145 | 164 |
| 30 Jun 21 | 961 | 203 | 130 | 154 |
| 31 Mar 21 | 844 | 184 | 109 | 130 |
| 31 Dec 20 | 785 | 170 | 98 | 138 |
| 30 Sep 20 | 700 | 169 | 92 | 130 |
| 30 Jun 20 | 596 | 143 | 88 | 127 |
| 31 Mar 20 | 544 | 129 | 86 | 126 |
| 31 Dec 19 | 503 | 111 | 84 | 121 |
| 30 Sep 19 | 466 | 96 | 76 | 106 |
| 30 Jun 19 | 445 | 83 | 98 | 147 |
| 31 Mar 19 | 410 | 74 | 80 | 117 |
| 31 Dec 18 | 408 | 73 | 66 | 92 |
| 31 Dec 17 | 317 | 46 | 53 | 77 |
| 31 Dec 16 | 201 | 17 | 46 | 51 |
Quality Earnings: 688166 has high quality earnings.
Growing Profit Margin: 688166's current net profit margins (16.7%) are lower than last year (23.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688166's earnings have grown significantly by 20.9% per year over the past 5 years.
Accelerating Growth: 688166's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 688166 had negative earnings growth (-16.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.5%).
Return on Equity
High ROE: 688166's Return on Equity (8.2%) is considered low.